Specialty medical injectable medication program, requirement and policy updates Sept. 2026

Review the following tables to determine changes to our specialty medical injectable medication programs and drug policy updates for Sept. 2026.

Sept. 18, 2026

Review the following tables for changes to our specialty medical injectable medication programs and drug policy updates.

Review at Launch

The following specialty medical injectable medications have been added to Review at Launch for UnitedHealthcare commercial business:

Medication Name HCPC(s)
Lytenava™
(bevacizumab-vikg)

J3490/J3590/C9399
Omlyclo®
(omalizumab-igec)
Biosimilar to Xolair®

Q5154

Medication Sourcing for Outpatient Hospital Providers Only

Effective Oct. 1, 2026, the following specialty medical injectable medication is being added to Medication Sourcing for Outpatient Hospital Providers Only for UnitedHealthcare commercial business:

Medication Name HCPC(s) Specialty Pharmacy
Bosaya
(denosumab-kyqq)
Biosimilar to Prolia®

Q5161
Optum Specialty Pharmacy
Ospomyv™
(denosumab-dssb)
Biosimilar to Prolia

Q5159
Caremark (CVS Specialty)
Qivigy®
(immune globulin intravenous, human-kthm)

J1577

 Accredo Health Group
Optum Infusion

For questions, please contact your broker or UnitedHealthcare representative.

More articles

Broker - Page template - More news Experience Fragment

Current broker or employer group client?

Access uhceservices to check commissions, manage eligibility, request ID cards and more.

Sign in